(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Hostess Brands, Aspen Group, and Verb Technology Company.

The three biggest losers today are NASDAQ TEST STOCK, SCWorx Corp., and Veru.

Winners today

1. Hostess Brands (TWNKW) – 41.59%

Hostess Brands, Inc., a packaged food company, develops, manufactures, markets, sells, and distributes fresh sweet baked goods in the United States. It primarily offer a range of snack cakes, donuts, sweet rolls, breakfast pastries, snack pies, and related products. The company operates in two segments, Sweet Baked Goods and In-Store Bakery. The Sweet Baked Goods segment offers fresh and frozen sweet baked goods and bread products under the Hostess, Dolly Madison, Cloverhill, and Big Texas brands, as well as store branded products. The In-Store Bakery segment primarily provides Superior on Main branded eclairs, madeleines, brownies, and iced cookies in the bakery section of grocery and club stores. The company was formerly known as Gores Holdings, Inc. and changed its name to Hostess Brands, Inc. in November 2016. Hostess Brands, Inc. was founded in 1919 and is based in Lenexa, Kansas.

NASDAQ ended the session with Hostess Brands rising 41.59% to $3.20 on Wednesday while NASDAQ fell 1.53% to $13,469.13.

PE Ratio

Hostess Brands has a trailing twelve months price to earnings ratio of 5.15. Meaning, the purchaser of the share is investing $5.15 for every dollar of annual earnings.

Moving Average

Hostess Brands’s value is below its 50-day moving average of $3.36 and way higher than its 200-day moving average of $2.53.

Volume

Today’s last reported volume for Hostess Brands is 29718 which is 70.4% below its average volume of 100427.

Yearly Top and Bottom Value

Hostess Brands’s stock is valued at $3.20 at 17:32 EST, way below its 52-week high of $4.02 and way higher than its 52-week low of $1.12.

More news about Hostess Brands.

2. Aspen Group (ASPU) – 14.35%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group rising 14.35% to $0.18 on Wednesday while NASDAQ slid 1.53% to $13,469.13.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.47.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Aspen Group’s stock is considered to be oversold (<=20).

Sales Growth

Aspen Group’s sales growth is negative 24% for the ongoing quarter and negative 29.3% for the next.

Revenue Growth

Year-on-year quarterly revenue growth declined by 17.8%, now sitting on 70.92M for the twelve trailing months.

More news about Aspen Group.

3. Verb Technology Company (VERBW) – 11.18%

NASDAQ ended the session with Verb Technology Company rising 11.18% to $0.02 on Wednesday, after five consecutive sessions in a row of losses. NASDAQ slid 1.53% to $13,469.13, following the last session’s downward trend on what was an all-around negative trend trading session today.

Yearly Top and Bottom Value

Verb Technology Company’s stock is valued at $0.02 at 17:32 EST, higher than its 52-week high of $0.02.

More news about Verb Technology Company.

4. FibroGen (FGEN) – 10.42%

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

NASDAQ ended the session with FibroGen rising 10.42% to $0.87 on Wednesday, following the last session’s upward trend. NASDAQ slid 1.53% to $13,469.13, following the last session’s downward trend on what was an all-around down trend exchanging session today.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-2.91.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1015.79%.

More news about FibroGen.

5. NeuroMetrix (NURO) – 7.79%

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

NASDAQ ended the session with NeuroMetrix jumping 7.79% to $0.71 on Wednesday while NASDAQ slid 1.53% to $13,469.13.

Earnings Per Share

As for profitability, NeuroMetrix has a trailing twelve months EPS of $-0.73.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.14%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NeuroMetrix’s stock is considered to be overbought (>=80).

Earnings Before Interest, Taxes, Depreciation, and Amortization

NeuroMetrix’s EBITDA is -1.88.

Moving Average

NeuroMetrix’s worth is way under its 50-day moving average of $0.83 and way below its 200-day moving average of $1.28.

Yearly Top and Bottom Value

NeuroMetrix’s stock is valued at $0.71 at 17:32 EST, way below its 52-week high of $3.45 and way above its 52-week low of $0.64.

More news about NeuroMetrix.

6. Nano Dimension (NNDM) – 7.11%

Nano Dimension Ltd., together with its subsidiaries, provides additive electronics in Israel and internationally. The company offers 3D printers, comprising DragonFly IV that produces Hi-PEDs by depositing proprietary conductive and dielectric substances, as well as integrates in-situ capacitors, antennas, coils, transformers, and electromechanical components; digital light processing printers (DLP) that achieves production-grade polymer and composite parts; and admaflex that utilizes a patented DLP foil system that fabricates ceramic and metal parts. It also provides additive electronics robotics and control systems, which includes surface-mount-technology, an electronics assembly equipment for electronic components on Hi-PEDs and PCBs, catering to various manufacturing and volume requirements; and ink delivery systems controls electronics, software, and ink delivery systems for digital printing. In addition, the company offers software to provide engineers with the tools to bring precision and electrical parts from design-to-manufacturing, as well as sells various materials that are developed in-house. Nano Dimension Ltd. was incorporated in 1960 and is headquartered in Ness Ziona, Israel.

NASDAQ ended the session with Nano Dimension jumping 7.11% to $2.71 on Wednesday, following the last session’s upward trend. NASDAQ fell 1.53% to $13,469.13, following the last session’s downward trend on what was an all-around bearish trend exchanging session today.

Earnings Per Share

As for profitability, Nano Dimension has a trailing twelve months EPS of $-0.53.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -11.67%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Nano Dimension’s EBITDA is -4.83.

More news about Nano Dimension.

7. Beyond Air (XAIR) – 6.83%

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops inhaled nitric oxide (NO) to treat respiratory infections, and gaseous NO to treat solid tumors. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of lung infections, persistent pulmonary hypertension of the newborn, severe acute respiratory syndrome coronavirus 2, bronchiolitis, and nontuberculous mycobacteria.The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.

NASDAQ ended the session with Beyond Air jumping 6.83% to $2.97 on Wednesday while NASDAQ fell 1.53% to $13,469.13.

Earnings Per Share

As for profitability, Beyond Air has a trailing twelve months EPS of $-1.72.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -113.68%.

Yearly Top and Bottom Value

Beyond Air’s stock is valued at $2.97 at 17:32 EST, way under its 52-week high of $9.28 and way higher than its 52-week low of $2.55.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Beyond Air’s EBITDA is 915.98.

Volume

Today’s last reported volume for Beyond Air is 611822 which is 8.84% above its average volume of 562123.

More news about Beyond Air.

8. WW International (WW) – 6.69%

WW International, Inc. provides weight management products and services worldwide. The company operates in four segments: North America, Continental Europe, United Kingdom, and Other. It offers a range of nutritional, activity, behavioral, and lifestyle tools and approaches products and services. The company also provides various digital subscription products to wellness and weight management business, which provide interactive and personalized resources that allow users to follow its weight management program via its Web-based and mobile app products, including personal coaching and digital products; and allows members to inspire and support each other by sharing their experiences with other people on weight management and wellness journeys. In addition, it offers various consumer products, including bars, snacks, cookbooks, kitchen tools, and other products. Further, the company licenses its trademarks and other intellectual property in food, beverages, and other consumer products and services. It offers products through its e-commerce platform, workshops, magazine subscriptions, retail partners, publishing, and third-party advertising in publications; and through Websites and sales from the By Mail product. The company was formerly known as Weight Watchers International, Inc. and changed its name to WW International, Inc. in September 2019. WW International, Inc. was founded in 1961 and is headquartered in New York, New York.

NASDAQ ended the session with WW International jumping 6.69% to $11.80 on Wednesday, following the last session’s upward trend. NASDAQ fell 1.53% to $13,469.13, following the last session’s downward trend on what was an all-around down trend exchanging session today.

Earnings Per Share

As for profitability, WW International has a trailing twelve months EPS of $-4.24.

Yearly Top and Bottom Value

WW International ‘s stock is valued at $11.80 at 17:32 EST, below its 52-week high of $12.13 and way above its 52-week low of $3.28.

Revenue Growth

Year-on-year quarterly revenue growth declined by 15.8%, now sitting on 942.37M for the twelve trailing months.

More news about WW International .

9. Wave Life Sciences Ltd. (WVE) – 6.18%

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics; and research, development, and develop antisense oligonucleotides. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

NASDAQ ended the session with Wave Life Sciences Ltd. rising 6.18% to $5.33 on Wednesday while NASDAQ dropped 1.53% to $13,469.13.

Earnings Per Share

As for profitability, Wave Life Sciences Ltd. has a trailing twelve months EPS of $-1.22.

Yearly Top and Bottom Value

Wave Life Sciences Ltd.’s stock is valued at $5.33 at 17:32 EST, way below its 52-week high of $7.12 and way above its 52-week low of $3.04.

Revenue Growth

Year-on-year quarterly revenue growth grew by 5794.9%, now sitting on 36.56M for the twelve trailing months.

Volume

Today’s last reported volume for Wave Life Sciences Ltd. is 309685 which is 17.88% below its average volume of 377125.

Moving Average

Wave Life Sciences Ltd.’s value is way above its 50-day moving average of $4.49 and way above its 200-day moving average of $4.44.

More news about Wave Life Sciences Ltd..

10. Pinterest (PINS) – 5.72%

Pinterest, Inc. operates as a visual discovery engine in the United States and internationally. The company's engine allows people to find ideas, such as recipes, home and style inspiration, and others; provides video, product, and idea pins; and offers organizing and planning tools. It shows organic recommendations and advertising engine based on pinners tastes and preferences; and enables pinners with shoppable product pins, which include price, color, and size that redirect to retailer websites. The company was formerly known as Cold Brew Labs Inc. and changed its name to Pinterest, Inc. in April 2012. Pinterest, Inc. was incorporated in 2008 and is headquartered in San Francisco, California.

NYSE ended the session with Pinterest rising 5.72% to $27.71 on Wednesday while NYSE slid 0.44% to $15,859.62.

Earnings Per Share

As for profitability, Pinterest has a trailing twelve months EPS of $-0.44.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 81.8% and 62.1%, respectively.

More news about Pinterest.

Losers Today

1. NASDAQ TEST STOCK (ZVZZT) – -87.17%

NASDAQ ended the session with NASDAQ TEST STOCK dropping 87.17% to $75.93 on Wednesday while NASDAQ dropped 1.53% to $13,469.13.

Yearly Top and Bottom Value

NASDAQ TEST STOCK’s stock is valued at $75.93 at 17:32 EST, way under its 52-week high of $97.98 and way above its 52-week low of $24.77.

More news about NASDAQ TEST STOCK.

2. SCWorx Corp. (WORX) – -13.96%

SCWorx Corp. provides software solutions for the management of health care providers' foundational business applications in the United States. The company provides services related to repair, normalization, and interoperability of information, as well as big data analytics model that provides Web portal for display, and reporting and analysis of the information contained within the data warehouse. It also offers various software solutions and services, such as virtualized item master file repair, expansion, and automation; electronic medical record management, a module that integrates the advanced data attributes created in the item master to the electronic medical records; charge description master management(CDM), a module, which assists healthcare providers by integrating the CDM data into the workflow of the hospitals purchasing systems; contract management, a module that assists healthcare providers to establish a contract management system and to provide care to patients; request for proposal automation solution; rebate management; ScanWorx, a mobile perioperative closed loop scanning solution; and data integration and warehousing, as well as solutions for integration of acquired businesses, which enable deployment of a virtual item master files. The company sells its solutions and services to hospitals and health systems through its distribution and reseller partnerships. In addition, it provides CageTix, a ticketing platform for mixed martial arts industry. Further, the company focuses on selling rapid test kits for COVID-19; and personal protective equipment. SCWorx Corp. is based in New York, New York.

NASDAQ ended the session with SCWorx Corp. sliding 13.96% to $0.22 on Wednesday, following the last session’s downward trend. NASDAQ dropped 1.53% to $13,469.13, following the last session’s downward trend on what was an all-around bearish trend exchanging session today.

Earnings Per Share

As for profitability, SCWorx Corp. has a trailing twelve months EPS of $-0.12.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -19.02%.

Yearly Top and Bottom Value

SCWorx Corp.’s stock is valued at $0.22 at 17:32 EST, way under its 52-week high of $0.96 and way higher than its 52-week low of $0.18.

More news about SCWorx Corp..

3. Veru (VERU) – -10.75%

Veru Inc., an oncology and urology biopharmaceutical company, engages in developing novel medicines for prostate cancer treatment and prostate cancer supportive care. The company's oncology drug candidates include VERU-111, an oral alpha and beta tubulin inhibitor, which is in a development Phase 1b/2 for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a Phase 2 clinical trial for the treatment of hot flashes in men undergoing androgen deprivation therapies; and VERU-100, a GnRH antagonist that is in planned Phase 2 clinical trial for the palliative treatment of advanced prostate cancer. Its urology specialty drug candidates are TADFIN, a tadalafil and finasteride combination of tablets and capsules for the treatment of men with lower urinary tract symptoms; and Tamsulosin XR capsules, which are tamsulosin capsules for treating benign prostatic hyperplasia. The company's commercial products include the FC2 Female/Internal condoms for the prevention of pregnancy and sexually transmitted infections; and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation. Its customers primarily include international agencies, government health agencies, ministries of health, and other governmental agencies, which purchase and distribute FC2 for use in HIV/AIDS prevention and family planning programs; and telemedicine providers who sell into the prescription channel in the United States. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. is headquartered in Miami, Florida.

NASDAQ ended the session with Veru sliding 10.75% to $0.83 on Wednesday while NASDAQ dropped 1.53% to $13,469.13.

Earnings Per Share

As for profitability, Veru has a trailing twelve months EPS of $-1.25.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -145.9%.

More news about Veru.

4. Vaccinex (VCNX) – -10.45%

Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), Huntington's disease, osteosarcoma, melanoma, and Alzheimer's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; and VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.

NASDAQ ended the session with Vaccinex sliding 10.45% to $0.16 on Wednesday, after three sequential sessions in a row of losses. NASDAQ fell 1.53% to $13,469.13, following the last session’s downward trend on what was an all-around down trend exchanging session today.

Earnings Per Share

As for profitability, Vaccinex has a trailing twelve months EPS of $-0.43.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -415.57%.

Volume

Today’s last reported volume for Vaccinex is 846800 which is 302.74% above its average volume of 210257.

More news about Vaccinex.

5. Canopy Growth (CGC) – -10.17%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth sliding 10.17% to $0.93 on Wednesday while NASDAQ fell 1.53% to $13,469.13.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-1.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -99.56%.

Volume

Today’s last reported volume for Canopy Growth is 61219200 which is 19.61% above its average volume of 51182100.

Revenue Growth

Year-on-year quarterly revenue growth grew by 2.6%, now sitting on 405.71M for the twelve trailing months.

Sales Growth

Canopy Growth’s sales growth for the current quarter is negative 12%.

More news about Canopy Growth.

6. Celsius Holdings (CELH) – -7.05%

Celsius Holdings, Inc. develops, processes, markets, distributes, and sells functional drinks and liquid supplements in the United States and internationally. The company offers various carbonated and non-carbonated functional energy drinks under the CELSIUS Originals name; dietary supplement in carbonated flavors, including apple jack'd, orangesicle, inferno punch, cherry lime, blueberry pomegranate, strawberry dragon fruit, tangerine grapefruit, and jackfruit under the CELSIUS HEAT name; and branched-chain amino acids functional energy drink that fuels muscle recovery under the CELSIUS BCCA+ENERGY name. It also provides CELSIUS On-the-Go, a powdered form of the active ingredients in functional energy drinks in individual On-The-Go packets and canisters; and sparkling grapefruit, cucumber lime, and orange pomegranate, as well as pineapple coconut, watermelon berry, and strawberries and cream non-carbonated functional energy drinks under the CELSIUS Sweetened name; and CELSIUS ready-to drink products. It distributes its products through direct-to-store delivery distributors and direct to retailers, include supermarkets, convenience stores, drug stores, nutritional stores, and mass merchants, as well as health clubs, spas, gyms, the military, and e-commerce websites. The company was formerly known as Vector Ventures, Inc. and changed its name to Celsius Holdings, Inc. in January 2007. Celsius Holdings, Inc. was founded in 2004 and is headquartered in Boca Raton, Florida.

NASDAQ ended the session with Celsius Holdings falling 7.05% to $183.93 on Wednesday, following the last session’s downward trend. NASDAQ fell 1.53% to $13,469.13, following the last session’s downward trend on what was an all-around down trend exchanging session today.

Is it worth investing in celsius holdings inc. (celh) based on wall street's bullish views?In terms of earnings estimate revisions for Celsius Holdings Inc., the Zacks Consensus Estimate for the current year has increased 2.3% over the past month to $1.86., Let’s take a look at what these Wall Street heavyweights have to say about Celsius Holdings Inc. (CELH Quick QuoteCELH – Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.

Earnings Per Share

As for profitability, Celsius Holdings has a trailing twelve months EPS of $-1.9.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.47%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 111.6%, now sitting on 952.02M for the twelve trailing months.

Moving Average

Celsius Holdings’s worth is way above its 50-day moving average of $154.25 and way higher than its 200-day moving average of $116.15.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Celsius Holdings’s EBITDA is 14.85.

More news about Celsius Holdings.

7. BeiGene (BGNE) – -6.72%

BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., Enlivex Therapeutics Ltd., Chime Biologics Limited, and Nanjing Leads Biolabs Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

NASDAQ ended the session with BeiGene dropping 6.72% to $194.82 on Wednesday, following the last session’s downward trend. NASDAQ dropped 1.53% to $13,469.13, following the last session’s downward trend on what was an all-around bearish trend trading session today.

Earnings Per Share

As for profitability, BeiGene has a trailing twelve months EPS of $-17.36.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.07%.

Volume

Today’s last reported volume for BeiGene is 180836 which is 22.54% below its average volume of 233461.

Yearly Top and Bottom Value

BeiGene’s stock is valued at $194.82 at 17:32 EST, way under its 52-week high of $280.62 and way above its 52-week low of $124.46.

Sales Growth

BeiGene’s sales growth is 60.7% for the current quarter and 83.3% for the next.

More news about BeiGene.

8. WISeKey International Holding AG (WKEY) – -6.67%

WISeKey International Holding AG, a cybersecurity company, provides integrated security solutions for the Internet of Things (IoT) and digital identity ecosystems in Switzerland, rest of Europe, North America, the Asia Pacific, and Latin America. The company operates through two segments, IoT and mPKI. It offers microcontrollers and microchips that provides identity to various connected devices; and managed public key infrastructure, which include digital identity, certificate management and signing solutions, and trust services, as well as offers digital certificates, software as a service (SaaS), software license, and post-contract customer support for cybersecurity applications. The company also develops, markets, hosts, and supports a range of solutions that enable secure digital identification of people, content, and objects by generating digital identities through its products and services in cybersecurity services, IoT, digital brand management, and mobile security, which enable clients to monetize their existing user bases, as well as expand its eco-system. In addition, the company operates ISTANA platform that uses cybersecurity SaaS business and semiconductor chips for securing the IoT market, as well as uses artificial intelligence to analyze data; and engages in financing, sales, and distribution activities. WISeKey International Holding AG was founded in 1999 and is headquartered in Zug, Switzerland.

NASDAQ ended the session with WISeKey International Holding AG dropping 6.67% to $2.10 on Wednesday, after three successive sessions in a row of losses. NASDAQ slid 1.53% to $13,469.13, following the last session’s downward trend on what was an all-around down trend exchanging session today.

Earnings Per Share

As for profitability, WISeKey International Holding AG has a trailing twelve months EPS of $-2.21.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -29.99%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 31.8%, now sitting on 23.81M for the twelve trailing months.

More news about WISeKey International Holding AG.

9. Willamette Valley Vineyards (WVVIP) – -5.89%

Willamette Valley Vineyards, Inc. produces and sells wine in the United States and internationally. It primarily offers Pinot Noir, Chardonnay, Pinot Gris, Pinot Blanc, Methode Champenoise Brut, Rose, and Riesling branded wines under the Willamette Valley Vineyards label; Semi-Sparkling Muscat branded wine under the Tualatin Estate Vineyards label; Syrah, Merlot, Cabernet Sauvignon, Grenache, Cabernet Franc, Tempranillo, Malbec, The Griffin, and Viognier branded wines under the Griffin Creek label; and Oregon Blossom branded wine under the Oregon Cellars label. The company also provides Pinot Noir and Chardonnay branded wine under the Elton label; Chrysologue, Merlot, and Cabernet Sauvignon branded wine under the Pambrun label; and Frontiere Syrah, Graviére Syrah, Voyageur Syrah, Bourgeois Grenache, and Voltigeur Viognier branded wine under the Maison Bleue label, as well as offers wines under the Natoma and Metis labels. It owns and leases approximately 914 acres of land. The company markets and sells its wine products directly through sales at the winery; and mailing lists, as well as through distributors and wine brokers. Willamette Valley Vineyards, Inc. was founded in 1983 and is headquartered in Turner, Oregon.

NASDAQ ended the session with Willamette Valley Vineyards dropping 5.89% to $4.47 on Wednesday while NASDAQ fell 1.53% to $13,469.13.

Earnings Per Share

As for profitability, Willamette Valley Vineyards has a trailing twelve months EPS of $0.135.

PE Ratio

Willamette Valley Vineyards has a trailing twelve months price to earnings ratio of 33.11. Meaning, the purchaser of the share is investing $33.11 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -2.06%.

Moving Average

Willamette Valley Vineyards’s worth is under its 50-day moving average of $4.60 and under its 200-day moving average of $4.93.

Volume

Today’s last reported volume for Willamette Valley Vineyards is 5706 which is 277.38% above its average volume of 1512.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Dec 5, 2022, the estimated forward annual dividend rate is 0.22 and the estimated forward annual dividend yield is 4.91%.

Yearly Top and Bottom Value

Willamette Valley Vineyards’s stock is valued at $4.47 at 17:32 EST, way under its 52-week high of $5.75 and above its 52-week low of $4.30.

More news about Willamette Valley Vineyards.

10. Novavax (NVAX) – -5.87%

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

NASDAQ ended the session with Novavax dropping 5.87% to $7.23 on Wednesday while NASDAQ dropped 1.53% to $13,469.13.

Earnings Per Share

As for profitability, Novavax has a trailing twelve months EPS of $-7.4.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 37.7% and 189.5%, respectively.

Yearly Top and Bottom Value

Novavax’s stock is valued at $7.23 at 17:32 EST, way below its 52-week high of $33.37 and way above its 52-week low of $5.61.

Sales Growth

Novavax’s sales growth is negative 69.2% for the ongoing quarter and 73.9% for the next.

More news about Novavax.

Stay up to date with our winners and losers daily report